__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
You may already see patients who need to reduce their LDL-C.
More than 3 in 4 patients with cardiovascular disease are currently not reaching the 1.8 mmol/L LDL-C target, remaining at high risk for cardiovascular events and death*4
NICE recommends LEQVIO®, within its licensed indication, as an option for the treatment of adult patients who:5
Have already had certain cardiovascular events (acute coronary syndrome such as myocardial infarction (MI) or unstable angina needing hospitalisation, coronary or other arterial revascularisation procedures, coronary heart disease, ischaemic stroke or peripheral arterial/artery disease (PAD))
Have persistently elevated LDL-C levels (≥2.6 mmol/L) despite maximum tolerated statins with or without other lipid-lowering therapies, or other lipid-lowering therapies when statins are not tolerated or are contraindicated
There are multiple opportunities to identify patients who are eligible for lipid optimisation with LEQVIO® in the inpatient and outpatient setting. See three different illustrative scenarios below:
Patient has been admitted to hospital multiple times due to cardiovascular events.† LDL-C still not at target despite statin initiation/up-titration to maximally tolerated statin.
Patient presents to the rapid access chest clinic with symptomatic cardiovascular disease and has been given an appointment for an elective PCI. Patient has LDL-C >2.6 mmol/L despite maximally tolerated statin.
Patient has been admitted to hospital following a cardiovascular event† and is attending a routine outpatient follow-up appointment post discharge. LDL-C still not at target despite statin initiation/up-titration to maximally tolerated statin.
These scenarios highlight potential patient presentations for LEQVIO® initiation and the opportunity to make every contact count in the secondary care setting.
In secondary care, LEQVIO® can be ordered directly from the Novartis Customer Care Team and a simple Blueteq form should be filled out for reimbursement
LEQVIO® is funded through a central NHS budget6
Preferred route (FP10HNC)‡6
Eligible patients are identified by a secondary care specialist in line with NICE guidance
Pre-filled syringes of LEQVIO® are ordered directly at the confidential contract price§
A decision to start LEQVIO®¶ is taken
LEQVIO® usage is reported under Commissioned Service Category Code 21; a Blueteq form and the DrPLCM are completed and provided for reimbursement7
| Stock can be ordered directly from the Novartis Customer Care Team (who can be contacted via telephone: 08457 419 442, fax: 08457 419 443 or e-mail: [email protected]), using the codes below:7 |
| Product name | EAN code | PIP code | ||
| LEQVIO® (inclisiran) | 7613421044237 | 4174751 |
LEQVIO® can also be supplied by the FP10 (HP) route (patients will need to collect the LEQVIO® pack at a community pharmacy and have it administered either at the hospital or by an appropriate primary care provider).6
LEQVIO® can be reimbursed via Blueteq – making reimbursement easy
The Blueteq form is short and easy to fill in, and can be accessed by scanning the QR code below:
This link will take you to a website over which Novartis Pharmaceuticals UK Limited has no ownership or control. Novartis Pharmaceuticals UK Limited accepts no responsibility for the content, accuracy, or your use of linked websites.
It includes just five, one-point questions focused on the patient’s diagnosis, history and LDL-C levels.
LEQVIO® eligible patients can be initiated and managed in secondary care, as well as primary care, to make every contact count.
As a secondary care specialist, you can initiate LEQVIO® for eligible patients and refer them for ongoing management in primary care, and keep the focus on more urgent, complex cases.
*National CVDPREVENT data covering the period up to March 2022. Data was received from 96.6% of GP practices, including approximately 18 million patients.4
†Events including but not limited to myocardial infarction, acute ischaemic stroke, transient ischaemic attack.
‡No prescription fee if prescribed and administered in the hospital.6
§Pack size: one pre-filled syringe.
¶After an initial dose, LEQVIO® is administered at 3 months, followed by every 6 months.2,3 As of April 2022, LEQVIO® will be added to the PbR-excluded drug list and will be reimbursed by NHS England.7
DrPLCM, drugs patient level contract monitoring data submission; EAN, European Article Number; GP, general practitioner; LDL-C, low-density lipoprotein cholesterol; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; PbR, payment by results; PCI, percutaneous coronary intervention.
References:
-
Steen DL et al. J Am Heart Assoc 2022;11(9):e022198.
-
LEQVIO® Great Britain Summary of Product Characteristics.
-
LEQVIO® Northern Ireland Summary of Product Characteristics.
-
Healthcare Quality Improvement Partnership. CVDPrevent Third Annual Audit. Available at: https://www.hqip.org.uk/wp-content/uploads/2023/03/Ref-376-CVDPREVENT-Th... [Accessed December 2023].
-
National Institute for Health and Care Excellence. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. Available at: https://www.nice.org.uk/guidance/ta733/resources/inclisiran-for-treating... [Accessed December 2023].
-
AAC. Implementing inclisiran (LEQVIO®) into the lipid management pathway. A toolkit for a population health management approach to adopting innovation. September 2021.
-
National Health Service. Summary information on the funding and supply of inclisiran (LEQVIO®). Available at: https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2023/04/B1913... [Accessed December 2023].
LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.